Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$58.75 USD
-0.03 (-0.05%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $58.79 +0.04 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RARE 58.75 -0.03(-0.05%)
Will RARE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Other News for RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tactical Resources Rises Amid Global REE Disruptions
Tactical Resources Strengthens Position Amid Rare Earth Elements Market Disruptions
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Bank of America Securities
Tracking Baker Brothers Portfolio - Q2 2024 Update